Company intelligence / Profile preview
Empyrean Therapeutics
La Jolla, California, USA
- Ownership
- Private
- Development stage
- Other
01
Overview
Empyrean’s lead program EMS‑312—a first-in-class TLR‑2 antagonist—was recently acquired from Eos Therapies and has shown promising preclinical activity in brain, pancreatic, breast, and other hard-to-treat cancers. The company also develops a tumor-selective radiosensitizer in preclinical development. No human clinical data reported as of May 2025.
- Therapeutic areas
- OncologyRare Diseases
- Modalities
- Small moleculesCell therapies (off-the-shelf/allogeneic)Gene editing/cellular engineering
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaboration with Eos Therapies for the transition of the EMS–312 assetPartnerships with academic centers including UCSD Center for Novel Therapeutics in La Jolla CA
Beyond the preview
Go deeper on Empyrean Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Empyrean Therapeutics.